Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

HIV vector production mediated by Rev protein transduction.

Claudia M Kowolik1, Priscilla Yam, Ying Yu

  • 1Department of Virology, Beckman Research Institute, City of Hope, 1500 E. Duarte Road, Duarte, California 91010, USA.

Molecular Therapy : the Journal of the American Society of Gene Therapy
|August 9, 2003
PubMed
Summary

Removing the HIV-1 rev gene enhances gene therapy vector safety. Supplying purified Rev protein allows for efficient vector production, improving clinical application safety.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association of Structural Maintenance of Chromosome-1A Phosphorylation with Progression of Breast Cancer.

Cells·2025
Same author

Ubiquitous Luciferase Expression in "Firefly Rats" Does Not Alter the Pancreatic Islet Morphology, Metabolism, and Function.

Cell transplantation·2023
Same author

Correction: Lin et al. Potent Anticancer Effects of Epidithiodiketopiperazine NT1721 in Cutaneous T Cell Lymphoma. <i>Cancers</i> 2021, <i>13</i>, 3367.

Cancers·2021
Same author

Potent Anticancer Effects of Epidithiodiketopiperazine NT1721 in Cutaneous T Cell Lymphoma.

Cancers·2021
Same author

Detection of CRISPR/Cas9-Generated Off-Target Effect by Integration-Defective Lentiviral Vector.

Methods in molecular biology (Clifton, N.J.)·2020
Same author

Recurrent secondary genomic alterations in desmoplastic small round cell tumors.

BMC medical genetics·2020

Area of Science:

  • Molecular Biology
  • Gene Therapy
  • Virology

Background:

  • HIV-1-based vectors are valuable for gene therapy due to their integration capabilities.
  • Safety concerns exist regarding replication-competent virus generation from recombination events during vector production.
  • Enhancing vector safety involves minimizing non-essential viral genome regions.

Purpose of the Study:

  • To determine if the HIV-1 rev gene is essential for HIV-1-based vector production.
  • To investigate methods for producing HIV-1-based vectors without the rev gene.
  • To assess the efficiency and safety of rev-gene-deleted vectors for gene therapy.

Main Methods:

  • Compared vector production efficiency using standard cotransfection versus supplying purified Rev protein.

Related Experiment Videos

  • Utilized TAT-Rev and Rev/Pep-1 for Rev protein delivery into vector-producing cells.
  • Assessed vector titers and transduction efficiencies in cell lines and primary cells.

    • Main Results:

    • The HIV-1 rev gene is dispensable for vector production when purified Rev protein is supplied.
    • 293T cells efficiently internalized TAT-Rev and Rev/Pep-1, yielding high-titer vector preparations.
    • Vectors produced without the rev gene showed comparable transduction efficiencies to standard vectors.

    Conclusions:

    • Eliminating the HIV-1 rev gene from vector constructs improves the safety profile of HIV-1-based vectors.
    • Supplying exogenous Rev protein, particularly via TAT-Rev or Rev/Pep-1, enables efficient production of safer vectors.
    • This strategy holds promise for enhancing the clinical applicability of HIV-1-based gene therapy vectors.